Related Experiment Videos
Prognostic markers in pheochromocytoma
M R Clarke1, R J Weyant, C G Watson
1Department of Pathology, University of Pittsburgh School of Medicine, PA, USA.
Human Pathology
|May 22, 1998
Summary
Malignant pheochromocytomas are difficult to distinguish. The MIB-1 labeling index, male gender, and extra-adrenal location are associated with malignancy, with MIB-1 being an independent predictor.
Area of Science:
- Endocrinology
- Oncology
- Pathology
Background:
- Distinguishing benign from malignant pheochromocytomas is challenging using standard clinical and histopathological features.
- There is a need for additional prognostic markers in the pathological assessment of pheochromocytomas.
Purpose of the Study:
- To investigate immunohistochemical markers for predicting malignancy in pheochromocytomas.
- To identify reliable prognostic indicators for pheochromocytoma pathology.
Main Methods:
- Immunohistochemical analysis of MIB-1, Bcl-2, cathepsin B, cathepsin D, bFGF, c-met, and type IV collagenase in 33 pheochromocytoma cases.
- Correlation of marker expression with clinical and histopathological features and long-term follow-up data to assess malignancy.
Main Results:
- MIB-1 labeling index (P = .0009), male gender (P = .008), extra-adrenal location (P = .03), increased tumor weight (P = .05), and younger age (P = .05) were associated with malignancy.
- MIB-1 labeling index >3% showed 100% specificity and 50% sensitivity for predicting malignancy.
- Neurofibromatosis (NF) cases were not malignant (P = .04).
Conclusions:
- MIB-1 labeling index is a significant independent predictor of malignancy in pheochromocytomas.
- Clinical factors like male gender and extra-adrenal location, alongside MIB-1 expression, aid in assessing pheochromocytoma malignancy risk.
- Further research into prognostic markers is warranted for improved patient management.